Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms

Experimental Hematology

Volumn 42, Issue 10, 2014, Pages 841-851

  Prick, Janine ^a,b   de Haan, Gerald ^b   Green, Anthony R ^a,c,d   Kent, David G ^a,c,d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; STAT1 PROTEIN; STAT5 PROTEIN; CYTOKINE; JAK2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR PROTEIN;

CANCER CLASSIFICATION; CANCER GROWTH; CANCER STEM CELL; CARCINOGENESIS; CELL HETEROGENEITY; CELL PROLIFERATION; CELL RENEWAL; CLONAL EVOLUTION; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; HEMATOPOIETIC STEM CELL; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; JAK2 GENE; MOLECULAR DYNAMICS; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PHENOTYPE; POINT MUTATION; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; STEM CELL EXPANSION; ANIMAL; BIOLOGICAL MODEL; CELL CLONE; CELL DIVISION; CELL TRANSFORMATION; CLASSIFICATION; ENZYMOLOGY; GENE TARGETING; GENETIC EPIGENESIS; GENETIC HETEROGENEITY; GENETIC SELECTION; GENETICS; METABOLISM; MISSENSE MUTATION; MOLECULAR EVOLUTION; MULTIPOTENT STEM CELL; MYELOID LEUKEMIA; MYELOPROLIFERATIVE DISORDER; PATHOLOGY; PHYSIOLOGY; RNA SPLICING;

ANIMALS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CLONE CELLS; CYTOKINES; EPIGENESIS, GENETIC; EVOLUTION, MOLECULAR; GENE DOSAGE; GENE KNOCK-IN TECHNIQUES; GENETIC HETEROGENEITY; HEMATOPOIETIC STEM CELLS; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOID; MODELS, GENETIC; MULTIPOTENT STEM CELLS; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PHENOTYPE; POINT MUTATION; RNA SPLICING; SELECTION, GENETIC; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84908378442     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2014.07.268     Document Type: Review

References (122)

1. Bryder D., Rossi D.J., Weissman I.L. Hematopoietic stem cells: The paradigmatic tissue-specific stem cell. Am J Pathol 2006, 169:338-346.
2. Simons B.D., Clevers H. Strategies for homeostatic stem cell self-renewal in adult tissues. Cell 2011, 145:851-862.
3. Nguyen L.V., Vanner R., Dirks P., Eaves C.J. Cancer stem cells: An evolving concept. Nat Rev Cancer 2012, 12:133-143.
4. Pietras E.M., Warr M.R., Passegue E. Cell cycle regulation in hematopoietic stem cells. J Cell Biol 2011, 195:709-720.
5. Dick J.E., Magli M.C., Huszar D., Phillips R.A., Bernstein A. Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice. Cell 1985, 42:71-79.
6. Lemischka I.R., Raulet D.H., Mulligan R.C. Developmental potential and dynamic behavior of hematopoietic stem cells. Cell 1986, 45:917-927.
7. Copley M.R., Beer P.A., Eaves C.J. Hematopoietic stem cell heterogeneity takes center stage. Cell Stem Cell 2012, 10:690-697.
8. Muller-Sieburg C.E., Sieburg H.B. Clonal diversity of the stem cell compartment. Curr Opin Hematol 2006, 13:243-248.
9. Moore K.A., Lemischka I.R. Stem cells and their niches. Science 2006, 311:1880-1885.
10. Roeder I., Kamminga L.M., Braesel K., Dontje B., de Haan G., Loeffler M. Competitive clonal hematopoiesis in mouse chimeras explained by a stochastic model of stem cell organization. Blood 2005, 105:609-616.
11. Dykstra B., Kent D., Bowie M., et al. Long-term propagation of distinct hematopoietic differentiation programs invivo. Cell Stem Cell 2007, 1:218-229.
12. Benz C., Copley M.R., Kent D.G., et al. Hematopoietic stem cell subtypes expand differentially during development and display distinct lymphopoietic programs. Cell Stem Cell 2012, 10:273-283.
13. Beerman I., Bhattacharya D., Zandi S., et al. Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion. Proc Natl Acad Sci USA 2010, 107:5465-5470.
14. Challen G.A., Boles N.C., Chambers S.M., Goodell M.A. Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. Cell Stem Cell 2010, 6:265-278.
15. Kent D.G., Copley M.R., Benz C., et al. Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential. Blood 2009, 113:6342-6350.
16. Morita Y., Ema H., Nakauchi H. Heterogeneity and hierarchy within the most primitive hematopoietic stem cell compartment. J Exp Med 2010, 207:1173-1182.
17. Ema H., Morita Y., Suda T. Heterogeneity and hierarchy of hematopoietic stem cells. Exp Hematol 2014, 42:74-82.e2.
18. Anderson K., Lutz C., van Delft F.W., et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011, 469:356-361.
19. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
20. Burrell R.A., McGranahan N., Bartek J., Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013, 501:338-345.
21. Crockford A., Jamal-Hanjani M., Hicks J., Swanton C. Implications of intratumour heterogeneity for treatment stratification. J Pathol 2014, 232:264-273.
22. Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell 2011, 144:646-674.
23. Notta F., Mullighan C.G., Wang J.C., et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011, 469:362-367.
24. Griffin J.D., Lowenberg B. Clonogenic cells in acute myeloblastic leukemia. Blood 1986, 68:1185-1195.
25. Dick J.E. Stem cell concepts renew cancer research. Blood 2008, 112:4793-4807.
26. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
27. Kreso A., Dick J.E. Evolution of the cancer stem cell model. Cell Stem Cell 2014, 14:275-291.
28. Quintana E., Shackleton M., Foster H.R., et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010, 18:510-523.
29. Charles N., Ozawa T., Squatrito M., et al. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 2010, 6:141-152.
30. Kelly P.N., Dakic A., Adams J.M., Nutt S.L., Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007, 317:337.
31. Dontu G., Al-Hajj M., Abdallah W.M., Clarke M.F., Wicha M.S. Stem cells in normal breast development and breast cancer. Cell Prolif 2003, 36(Suppl 1):59-72.
32. Hemmati H.D., Nakano I., Lazareff J.A., et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 2003, 100:15178-15183.
33. Singh S.K., Clarke I.D., Terasaki M., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63:5821-5828.
34. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
35. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
36. Johnsen H.E., Kjeldsen M.K., Urup T., et al. Cancer stem cells and the cellular hierarchy in haematological malignancies. Eur J Cancer 2009, 45(Suppl 1):194-201.
37. Pellicano F., Sinclair A., Holyoake T.L. In search of CML stem cells' deadly weakness. Curr Hematol Malig Rep 2011, 6:82-87.
38. Campbell P.J., Green A.R. The myeloproliferative disorders. N Engl J Med 2006, 355:2452-2466.
39. Adamson J.W., Fialkow P.J., Murphy S., Prchal J.F., Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. NEngl J Med 1976, 295:913-916.
40. Fialkow P.J., Faguet G.B., Jacobson R.J., Vaidya K., Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981, 58:916-919.
41. Jacobson R.J., Salo A., Fialkow P.J. Agnogenic myeloid metaplasia: A clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978, 51:189-194.
42. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
43. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
44. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
45. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
46. Passamonti F., Elena C., Schnittger S., et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 2011, 117:2813-2816.
47. Scott L.M., Tong W., Levine R.L., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007, 356:459-468.
48. Pikman Y., Lee B.H., Mercher T., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006, 3:e270.
49. Rumi E., Pietra D., Guglielmelli P., et al. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood 2013, 121:4388-4395.
50. Klampfl T., Gisslinger H., Harutyunyan A.S., et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013, 369:2379-2390.
51. Nangalia J., Massie C.E., Baxter E.J., et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013, 369:2391-2405.
52. Spivak J.L., Barosi G., Tognoni G., et al. Chronic myeloproliferative disorders. Hematology Am Soc Hematol Educ Program 2003, 200-224.
53. Godfrey A.L., Chen E., Pagano F., et al. JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood 2012, 120:2704-2707.
54. Rossi D., Deambrogi C., Capello D., et al. JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders. Br J Haematol 2006, 135:267-268.
55. Kent D.G., Li J., Tanna H., et al. Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion. PLoS Biol 2013, 11:e1001576.
56. Kota J., Caceres N., Constantinescu S.N. Aberrant signal transductionpathways in myeloproliferative neoplasms. Leukemia 2008, 22:1828-1840.
57. Them N.C., Kralovics R. Genetic basis of MPN: Beyond JAK2-V617F. Curr Hematol Malig Rep 2013, 8:299-306.
58. Viny A.D., Levine R.L. Genetics of myeloproliferative neoplasms. Cancer J 2014, 20:61-65.
59. Oh S.T., Simonds E.F., Jones C., et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010, 116:988-992.
60. Sanada M., Suzuki T., Shih L.Y., et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009, 460:904-908.
61. Yoshida K., Sanada M., Shiraishi Y., et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011, 478:64-69.
62. Brecqueville M., Rey J., Bertucci F., et al. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer 2012, 51:743-755.
63. Abdel-Wahab O., Manshouri T., Patel J., et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010, 70:447-452.
64. Lundberg P., Karow A., Nienhold R., et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014, 123:2220-2228.
65. Vannucchi A.M., Lasho T.L., Guglielmelli P., et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013, 27:1861-1869.
66. Cleary C., Kralovics R. Molecular basis and clonal evolution of myeloproliferative neoplasms. Clin Chem Lab Med 2013, 51:1889-1896.
67. Harutyunyan A., Klampfl T., Cazzola M., Kralovics R. P53 Lesions in leukemic transformation. N Engl J Med 2011, 364:488-490.
68. Tefferi A., Lasho T.L., Finke C.M., et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: Clinical, cytogenetic and molecular comparisons. Leukemia 2014, 28:1472-1477.
69. Rampal R., Al-Shahrour F., Abdel-Wahab O., et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 2014, 123:e123-e133.
70. Beer P.A., Erber W.N., Campbell P.J., Green A.R. How I treat essential thrombocythemia. Blood 2011, 117:1472-1482.
71. Wilkins B.S., Erber W.N., Bareford D., et al. Bone marrow pathology in essential thrombocythemia: Interobserver reliability and utility for identifying disease subtypes. Blood 2008, 111:60-70.
72. Li J., Kent D.G., Chen E., Green A.R. Mouse models of myeloproliferative neoplasms: JAK of all grades. Dis Model Mech 2011, 4:311-317.
73. Van Etten R.A., Koschmieder S., Delhommeau F., et al. The Ph-positive and Ph-negative myeloproliferative neoplasms: Some topical pre-clinical and clinical issues. Haematologica 2011, 96:590-601.
74. Akada H., Yan D., Zou H., Fiering S., Hutchison R.E., Mohi M.G. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010, 115:3589-3597.
75. Marty C., Lacout C., Martin A., et al. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood 2010, 116:783-787.
76. Mullally A., Lane S.W., Ball B., et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 2010, 17:584-596.
77. Li J., Spensberger D., Ahn J.S., et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 2010, 116:1528-1538.
78. Kubovcakova L., Lundberg P., Grisouard J., et al. Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model. Blood 2013, 121:1188-1199.
79. Mullally A., Poveromo L., Schneider R.K., Al-Shahrour F., Lane S.W., Ebert B.L. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. Blood 2012, 120:166-172.
80. Scott L.M., Scott M.A., Campbell P.J., Green A.R. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera,but not essential thrombocythemia. Blood 2006, 108:2435-2437.
81. Li J., Kent D.G., Godfrey A.L., et al. JAK2V617F-homozygosity drives a phenotypic switch between myeloproliferative neoplasms in a murine model, but is insufficient to sustain clonal expansion. Blood 2014, 123:3139-3151.
82. Laubach J.P., Fu P., Jiang X., Salter K.H., Potti A., Arcasoy M.O. Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation. Exp Hematol 2009, 37:1411-1422.
83. Levine R.L., Pardanani A., Tefferi A., Gilliland D.G. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007, 7:673-683.
84. Chen E., Beer P.A., Godfrey A.L., et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell 2010, 18:524-535.
85. Funakoshi-Tago M., Tago K., Abe M., Sonoda Y., Kasahara T. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant. J Biol Chem 2010, 285:5296-5307.
86. Yan D., Hutchison R.E., Mohi G. Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood 2012, 119:3539-3549.
87. Walz C., Ahmed W., Lazarides K., et al. Essential role for Stat5a/binmyeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood 2012, 119:3550-3560.
88. Bellucci S., Harousseau J.L., Brice P., Tobelem G. Treatment of essential thrombocythaemia by alpha 2a interferon. Lancet 1988, 2:960-961.
89. Silver R.T. Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet 1988, 2:403.
90. Kiladjian J.J., Cassinat B., Chevret S., et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008, 112:3065-3072.
91. Quintas-Cardama A., Kantarjian H., Manshouri T., et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009, 27:5418-5424.
92. Essers M.A., Offner S., Blanco-Bose W.E., et al. IFNalpha activates dormant haematopoietic stem cells invivo. Nature 2009, 458:904-908.
93. Sato T., Onai N., Yoshihara H., Arai F., Suda T., Ohteki T. Interferon regulatory factor-2 protects quiescent hematopoietic stem cellsfrom type I interferon-dependent exhaustion. Nat Med 2009, 15:696-700.
94. Hasan S., Lacout C., Marty C., et al. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNalpha. Blood 2013, 122:1464-1477.
95. Mullally A., Bruedigam C., Poveromo L., et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-alpha in a murine model of polycythemia vera. Blood 2013, 121:3692-3702.
96. Jones A.V., Cross N.C. Inherited predisposition to myeloproliferative neoplasms. Ther Adv Hematol 2013, 4:237-253.
97. Kralovics R., Stockton D.W., Prchal J.T. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 2003, 102:3793-3796.
98. Levine R.L., Gilliland D.G. Myeloproliferative disorders. Blood 2008, 112:2190-2198.
99. Jones A.V., Chase A., Silver R.T., et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009, 41:446-449.
100. Pardanani A., Fridley B.L., Lasho T.L., Gilliland D.G., Tefferi A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 2008, 111:2785-2789.
101. Fialkow P.J., Jacobson R.J., Papayannopoulou T. Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977, 63:125-130.
102. Xu X., Zhang Q., Luo J., et al. JAK2(V617F): Prevalence in a large Chinese hospital population. Blood 2007, 109:339-342.
103. Ruella M., Salmoiraghi S., Risso A., et al. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: A biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy. Exp Hematol 2013, 41:627-634.
104. Ishii T., Zhao Y., Sozer S., et al. Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice. Exp Hematol 2007, 35:1633-1640.
105. Campbell P.J., Baxter E.J., Beer P.A., et al. Mutation of JAK2 in the myeloproliferative disorders: Timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 2006, 108:3548-3555.
106. Theocharides A., Boissinot M., Girodon F., et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007, 110:375-379.
107. Akada H., Akada S., Hutchison R.E., Mohi G. Erythroid lineage-restricted expression of Jak2V617F is sufficient to induce a myeloproliferative disease in mice. Haematologica 2012, 97:1389-1393.
108. Wilson A., Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006, 6:93-106.
109. Anand S., Stedham F., Beer P., et al. Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms. Blood 2011, 118:177-181.
110. James C., Mazurier F., Dupont S., et al. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. Blood 2008, 112:2429-2438.
111. Jamieson C.H., Gotlib J., Durocher J.A., et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci USA 2006, 103:6224-6229.
112. Moliterno A.R., Williams D.M., Rogers O., Isaacs M.A., Spivak J.L. Phenotypic variability within the JAK2 V617F-positive MPD: Roles of progenitor cell and neutrophil allele burdens. Exp Hematol 2008, 36:1480-1486.
113. Sloma I., Jiang X., Eaves A.C., Eaves C.J. Insights into the stem cells of chronic myeloid leukemia. Leukemia 2010, 24:1823-1833.
114. Jamieson C.H., Ailles L.E., Dylla S.J., et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004, 351:657-667.
115. Sirard C., Lapidot T., Vormoor J., et al. Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. Blood 1996, 87:1539-1548.
116. Sanz M.A., Iacoboni G., Montesinos P. Acute promyelocytic leukemia: Do we have a new front-line standard of treatment?. Curr Oncol Rep 2013, 15:445-449.
117. Suzuki N., Yamazaki S., Ema H., Yamaguchi T., Nakauchi H., Takaki S. Homeostasis of hematopoietic stem cells regulated by the myeloproliferative disease associated-gene product Lnk/Sh2b3 via Bcl-xL. Exp Hematol 2012, 40:166-174.e3.
118. Akada H., Akada S., Gajra A., et al. Efficacy of vorinostat in a murine model of polycythemia vera. Blood 2012, 119:3779-3789.
119. Pellicano F., Holyoake T.L. Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks. J Exp Med 2011, 208:2155-2158.
120. Carbuccia N., Murati A., Trouplin V., et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009, 23:2183-2186.
121. Sabnis A.J., Cheung L.S., Dail M., et al. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol 2009, 7:e59.
122. Schemionek M., Elling C., Steidl U., et al. BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood 2010, 115:3185-3195.